Orchid Pharma Limited (ORCHPHARMA) AI Stock Analysis

• Market Cap: ₹36.55B
• Dividend Yield: N/A
• Average Volume (3M): 11.23K
• Price to Earnings (P/E): 42.9
• Beta (1Y): 1.47
• Revenue Growth: -3.45%
• EPS Growth: -23.60%
• Country: IN
• Employees: 871
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.90
• Shares Outstanding: 50,719,105
• 10 Day Avg. Volume: 24,518
• 30 Day Avg. Volume: 11,233
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹785.00
• Price Target Upside: 8.94% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 63 Neutral
• Price Target: ₹785.00 ▲(8.94% Upside)

Orchid Pharma's strong financial performance, particularly in revenue growth and balance sheet stability, is offset by cash flow challenges and high valuation. Technical indicators suggest neutral market sentiment. The absence of earnings call and corporate events data limits further insights.

Orchid Pharma Limited Business Overview & Revenue Model

Company Description

Orchid Pharma Limited (ORCHPHARMA) is a pharmaceutical company engaged in the development, manufacture, and marketing of a diverse range of bulk actives, formulations, and nutraceuticals. The company operates within the healthcare and pharmaceutical sectors, focusing on anti-infectives, including cephalosporin, and non-antibiotic products across various therapeutic segments. Orchid Pharma serves a broad market, including both domestic and international clients, leveraging its advanced research and development capabilities.

How the Company Makes Money

Orchid Pharma Limited generates revenue primarily through the sale of its pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms. The company's revenue streams are diversified across different therapeutic categories, with a significant focus on anti-infective drugs. Orchid Pharma has established partnerships and supply agreements with pharmaceutical companies globally, contributing to its earnings through both direct sales and licensing agreements. Additionally, the company's investment in research and development facilitates the creation of proprietary formulations, further enhancing its revenue potential.

Orchid Pharma Limited Financial Statement Overview

Summary

Orchid Pharma shows strong revenue growth and a healthy gross profit margin. The balance sheet is robust with low leverage, but cash flow challenges, including negative free cash flow, need addressing.

Income Statement

Orchid Pharma has demonstrated strong revenue growth, with a 12.54% increase in the last year. The gross profit margin is healthy at 40.97%, and the company has managed to turn around its net income from previous losses to a net profit margin of 10.81%. However, the EBIT margin of 27.85% and EBITDA margin of 15.69% indicate room for improvement in operational efficiency.

Balance Sheet

The company's balance sheet is robust, with an equity ratio of 75.08% suggesting strong financial stability. The debt-to-equity ratio is low at 0.14, indicating low leverage. The return on equity (ROE) is 7.86%, which, while positive, indicates moderate return generation from equity.

Cash Flow

Cash flow analysis shows potential stress, with a substantial decline in free cash flow from last year. The operating cash flow to net income ratio of 0.19 suggests low conversion of income into cash. Free cash flow has turned negative, which could pose challenges for future investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	9.02B	9.22B	8.19B	6.66B	5.60B	4.50B
Gross Profit	3.48B	3.78B	3.16B	2.65B	2.32B	2.09B
EBITDA	1.55B	1.45B	1.42B	1.43B	635.82M	658.74M
Net Income	1.11B	996.57M	921.66M	463.18M	-19.51M	-1.17B
Balance Sheet
Total Assets	0.00	16.88B	15.54B	12.25B	11.11B	12.37B
Cash, Cash Equivalents and Short-Term Investments	2.44B	1.83B	45.24M	275.21M	48.27M	315.15M
Total Debt	0.00	1.75B	1.35B	3.31B	2.68B	4.53B
Total Liabilities	-12.24B	4.21B	3.84B	5.37B	4.63B	5.84B
Stockholders Equity	12.24B	12.67B	11.69B	6.89B	6.47B	6.53B
Cash Flow
Free Cash Flow	0.00	-1.31B	611.77M	-665.75M	780.71M	229.82M
Operating Cash Flow	0.00	192.15M	1.26B	183.38M	924.75M	235.86M
Investing Cash Flow	0.00	-269.31M	-3.12B	-312.14M	1.13B	672.05M
Financing Cash Flow	0.00	252.22M	1.67B	311.66M	-2.17B	-1.65B

Orchid Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 720.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ORCHPHARMA, the sentiment is Negative. The current price of 720.6 is below the 20-day moving average (MA) of 727.12, below the 50-day MA of 740.51, and below the 200-day MA of 974.10, indicating a bearish trend. The MACD of -0.64 indicates Negative momentum. The RSI at 45.56 is Neutral, neither overbought nor oversold. The STOCH value of 32.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ORCHPHARMA.

Orchid Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADVENZYMES	69 Neutral	₹35.80B	26.15	9.23%	1.64%	5.89%	-1.30%
MOREPENLAB	67 Neutral	₹26.78B	28.68	10.21%	0.41%	2.12%	-25.99%
ORCHPHARMA	63 Neutral	₹36.55B	42.89	―	―	-3.45%	-23.60%
GUFICBIO	57 Neutral	₹35.81B	57.88	11.59%	0.03%	2.37%	-30.78%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%